Clinical trial
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for…
NCT00001873 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00001873 |
|---|---|
| Title | The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers |
| Official title | Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T-Cell Add-Back for Hematological Malignancies - Role of Cyclosporine |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hematologic Neoplasm, Multiple Myeloma, Myelodysplastic Syndrome |
| Intervention type | Device |
| Interventions | Isolex 300i plus MoAbs |
| Enrollment | 102 |
| Start date | Feb 22, 1999 |
| Primary completion | Dec 28, 2007 |
| Completion | Jun 13, 2017 |
| First posted | Nov 4, 1999 |
| Last update posted | Sep 26, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: